Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
No biomarker
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Marginal Zone Lymphoma
No biomarker
Marginal Zone Lymphoma
zanubrutinib
Sensitive: A1 - Approval
zanubrutinib
Sensitive
:
A1
zanubrutinib
Sensitive: A1 - Approval
zanubrutinib
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
pomalidomide + elotuzumab
Sensitive: A1 - Approval
pomalidomide + elotuzumab
Sensitive
:
A1
pomalidomide + elotuzumab
Sensitive: A1 - Approval
pomalidomide + elotuzumab
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
rituximab + acalabrutinib + bendamustine
Sensitive: A1 - Approval
rituximab + acalabrutinib + bendamustine
Sensitive
:
A1
rituximab + acalabrutinib + bendamustine
Sensitive: A1 - Approval
rituximab + acalabrutinib + bendamustine
Sensitive
:
A1
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
lisocabtagene maraleucel
Sensitive: A1 - Approval
lisocabtagene maraleucel
Sensitive
:
A1
lisocabtagene maraleucel
Sensitive: A1 - Approval
lisocabtagene maraleucel
Sensitive
:
A1
No biomarker
Non Small Cell Lung Cancer
No biomarker
Non Small Cell Lung Cancer
ramucirumab
Sensitive: A1 - Approval
ramucirumab
Sensitive
:
A1
ramucirumab
Sensitive: A1 - Approval
ramucirumab
Sensitive
:
A1
No biomarker
Non Small Cell Lung Cancer
No biomarker
Non Small Cell Lung Cancer
durvalumab
Sensitive: A1 - Approval
durvalumab
Sensitive
:
A1
durvalumab
Sensitive: A1 - Approval
durvalumab
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
No biomarker
Renal Cell Carcinoma
nivolumab + cabozantinib tablet
Sensitive: A1 - Approval
nivolumab + cabozantinib tablet
Sensitive
:
A1
nivolumab + cabozantinib tablet
Sensitive: A1 - Approval
nivolumab + cabozantinib tablet
Sensitive
:
A1
No biomarker
Malignant Pleural Mesothelioma
No biomarker
Malignant Pleural Mesothelioma
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
No biomarker
Mediastinal B Cell Lymphoma
No biomarker
Mediastinal B Cell Lymphoma
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.